High-protein nutrition drink for muscle in people with type 2 diabetes on incretin drugs
Tests a high-protein drink for muscle mass in overweight adults with type 2 diabetes.
Key facts
- Who runs it
- Joslin Diabetes Center
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 1 Jan 2026
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- protein supplement
- Record updated
- 29 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with type 2 diabetes and a BMI of 25 kg/m2 or higher who are about to start semaglutide, tirzepatide or dulaglutide. It tests a high-protein diabetes formula.
- Age
- 18 to 75 years
- Sex
- Men and women can join.
- Disease stage
- Type 2 diabetes diagnosed at least 3 months before screening; BMI of 25 kg/m2 or higher.
- Earlier treatment
- About to start treatment with semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) or dulaglutide (Trulicity).
Main reasons for not taking part
- Type 1 diabetes
- Kidney function (eGFR) below 60 milliliters/minute/1.73 m²
- Urine albumin-to-creatinine ratio (UACR) of 300 mg/g or higher
- Acute kidney injury in the 6 months before screening
- Allergy or intolerance to the HP-DSF shake or its ingredients
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Subject is between 18-75 years of age
- Subject was diagnosed with type 2 diabetes at least 3 months prior to screening
- Subject is about to start treatment with an IMD, a GLP-1 receptor agonist (RA) alone or a dual GLP-1/GIP RA. These treatments include either semaglutide (Ozempic®, Wegovy®), tirzepatide (Mounjaro®, Zepbound®), or dulaglutide (Trulicity®)
- Body mass index (BMI) is ≥ 25 kg/m2
Who cannot take part
- History of acute kidney injury (AKI) during the 6 months prior to screening g
- Subject has type 1 diabetes mellitus
- Intolerance or allergy to HP-DSF shake or to any of its ingredients
- Urine albumin-to-creatinine ratio (UACR) of 300 mg/g or higher
- Subject with estimated glomerular filtration rate <60 milliliters/minute/1.73 m²,
- Women who are pregnant or lactating or expect to be pregnant or lactating during the study period
- Women of childbearing potential who are not using highly effective contraceptive methods; -
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- Joslin Diabetes CenterBoston, United StatesContact: Marwa Al-Badri, MDTaking people
About the trial
What the trial wants to find out
A randomized clinical study to assess the efficacy of a high-protein diabetes specific formula (HPDSF) on lean muscle mass in overweight and obese patients with type 2 diabetes who are initiating treatment with incretin-mimetic drugs.
The 2 groups in the trial
- Participants will be instructed to drink two HP-DSF shakesTreatment being tested
Treatment: protein supplement
- Participants in this control group will follow the regular standard of diabetes careNo study treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluating the Efficacy of High-Protein Diabetes Specific Formula (HP-DSF) on Body Composition in Overweight/Obese Patients With Type 2 Diabetes Treated With Incretin Mimetic Drugs
- Plain-language title
- High-protein nutrition drink for muscle in people with type 2 diabetes on incretin drugsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07271043, who can take part
- Record updated
- 29 May 2026